Progress pics after a full year of treatment 1/18/2025
A 57-year-old user shared their one-year hair loss treatment progress using Minoxidil, Finasteride, Dutasteride, RU58841, KX-826, Keto shampoo, vitamins, and an iRestore helmet. They are considering simplifying their regimen to prescribed medications and feel uncertain about continuing despite seeing some progress.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity KX-826 and RU58841: do topical anti-androgens work?
KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.
community Ru-58841 or KX-826 (Pyrilutamide)?
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
community If ru58841 didn't work for me could KX-826 help?
RU58841 was ineffective for OP, who is considering adding KX-826 with finasteride. User8 suggests KX-826 may help when combined with minoxidil and dutasteride.
community KX826 is better than RU58841. A legitimate option for those who cant use fin or dut.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
community Which is safest carrier for topical antiandrogens (finasteride/kx-826/ru/dutasteride)
The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.
community Is there a GT20029 update? I’d have thought Kintor would release bad news of KX-826 with good news of GT20029.
The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research A systematic summary of survival and death signalling during the life of hair follicle stem cells
This review examines the life cycle, biomarkers, and functions of hair follicle stem cells, emphasizing their role in hair loss therapy and other skin and hair disorders, but reports no new clinical results.
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Системная терапия больных андрогенетической алопецией
Some treatments like minoxidil, finasteride, and dutasteride are effective for hair loss, but there's no agreed best treatment.
research Тіе Modern treatment of androgenetic alopecia
This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
research Андрогенетическая алопеция: патогенетические механизмы и подходы к лечению
This article reviews the pathophysiology and limited effectiveness of current treatments for androgenic alopecia, including finasteride, minoxidil, botulinum toxin A, and platelet-rich plasma, and highlights the need for new therapeutic approaches; it reports no new clinical findings.